Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy

Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy

Objective: Tumor necrosis factor-alpha (TNF-α), checkpoint inhibitors, and interleukin-17 (IL-17) are critical targets in inflammation and autoimmune diseases. Monoclonal antibodies (mAbs) have a successful portfolio in the treatment of chronic diseases. With the current progress in stem cells and...

Full description

Bibliographic Details
Main Authors: Ali Fallah, Hajar Estiri, Elizabeth Parrish, Mansoureh Soleimani, Sirous Zeinali, Azita Zadeh-Vakili
Format: Article
Language:English
Published: Royan Institute (ACECR), Tehran 2019-08-01
Series:Cell Journal
Subjects:
Gene Therapy
Genetic Vectors
Monoclonal Antibody
Secukinumab
Stem Cells
Online Access:https://celljournal.org/journal/article/fulltext/biosimilar-gene-therapy-investigational-assessment-of-secukinumab-gene-therapy.pdf

Internet

https://celljournal.org/journal/article/fulltext/biosimilar-gene-therapy-investigational-assessment-of-secukinumab-gene-therapy.pdf

Similar Items